{"id":11216,"date":"2020-09-22T00:00:00","date_gmt":"2020-09-22T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/janssen-depose-une-nouvelle-formulation-du-medicament-darzalex-faspro-pour-le-traitement-dune-maladie-rare-lamyloidose-a-chaine-legere\/"},"modified":"2025-08-19T08:28:18","modified_gmt":"2025-08-19T13:28:18","slug":"janssen-depose-une-nouvelle-formulation-du-medicament-darzalex-faspro-pour-le-traitement-dune-maladie-rare-lamyloidose-a-chaine-legere","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/09\/22\/janssen-depose-une-nouvelle-formulation-du-medicament-darzalex-faspro-pour-le-traitement-dune-maladie-rare-lamyloidose-a-chaine-legere\/","title":{"rendered":"JANSSEN D\u00c9POSE UNE NOUVELLE FORMULATION DU M\u00c9DICAMENT DARZALEX FASPRO POUR LE TRAITEMENT D\u2019UNE MALADIE RARE, L\u2019AMYLO\u00cfDOSE \u00c0 CHA\u00ceNE L\u00c9G\u00c8RE"},"content":{"rendered":"<p>Janssen a d\u00e9pos\u00e9 une nouvelle formulation du m\u00e9dicament Darzalex aux \u00c9tats-Unis pour traiter une maladie rare et potentiellement mortelle, <strong>l\u2019amylo\u00efdose<\/strong> \u00e0 cha\u00eene l\u00e9g\u00e8re (AL).<\/p>\n<p>L\u2019unit\u00e9 pharmaceutique de Johnson &amp; Johnson a d\u00e9clar\u00e9 avoir d\u00e9pos\u00e9 Darzalex Faspro (daratumumab+hyaluronidase), une formulation sous-cutan\u00e9e du m\u00e9dicament d\u00e9j\u00e0 approuv\u00e9e pour traiter plusieurs cancers du sang. Cliquez <strong><a href=\"https:\/\/pharmaphorum.com\/news\/janssen-files-new-darzalex-for-rare-disease-light-chain-amyloidosis\/\" target=\"_blank\" rel=\"noopener\">ici<\/a>&nbsp;<\/strong>(en anglais)&nbsp;pour lire la suite.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Janssen a d\u00e9pos\u00e9 une nouvelle formulation du m\u00e9dicament Darzalex aux \u00c9tats-Unis pour traiter une maladie rare et potentiellement mortelle, l\u2019amylo\u00efdose \u00e0 cha\u00eene l\u00e9g\u00e8re (AL). L\u2019unit\u00e9 pharmaceutique de Johnson &amp; Johnson a d\u00e9clar\u00e9 avoir d\u00e9pos\u00e9 Darzalex Faspro (daratumumab+hyaluronidase), une formulation sous-cutan\u00e9e du m\u00e9dicament d\u00e9j\u00e0 approuv\u00e9e pour traiter plusieurs cancers du sang. Cliquez ici&nbsp;(en anglais)&nbsp;pour lire la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11216","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11216"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11216\/revisions"}],"predecessor-version":[{"id":31310,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11216\/revisions\/31310"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}